当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

インデックス付き
  • 索引コペルニクス
  • Google スカラー
  • Jゲートを開く
  • Genamics JournalSeek
  • 中国国家知識基盤 (CNKI)
  • 電子ジャーナルライブラリ
  • レフシーク
  • ハムダード大学
  • エブスコ アリゾナ州
  • OCLC-WorldCat
  • 仮想生物学図書館 (vifabio)
  • パブロン
  • ジュネーブ医学教育研究財団
  • ユーロパブ
  • ICMJE
このページをシェアする

抽象的な

How We should Support Patients Decision Making at End of Life From a National Survey of Hospital Ethics Committees in Japan

Tomoko Kodama Kawashima

Objective: To overview frequent ethical issues arising in clinical setting and the role of hospital ethics committees (HECs) from a national survey in Japan.

Design: Cross sectional survey using questionnaire by post to 4,911 randomly selected hospitals throughout Japan.

Results: Among 1,555 hospitals responding to the survey, the most frequent ethical issue likely to arise in practice was end-of-life care (n = 1,022). A total of 787 hospitals (51.1%) reported that they already had an ethics committee in place and 259 hospitals (16.8%) were planning to establish HECs. Of existing HECs, 42% were engaged in consultation or advice regarding clinical aspects other than clinical research ethics. Measures to provide support for ethical issues in the clinical setting were “advice from hospital ethics committee” (38%), “documentation or guidelines” (26%), “telephone consultation with experts” (11%), and “staff education” (18%). Twenty-five percent of participating hospitals had no specific support for clinical ethics. The HEC members were composed mainly of medical professionals, with only 14% of HECs having ethicists on their panels. The meeting records of HECs were not often disclosed (fully disclosed 23%, partially disclosed 26%).

Conclusion: The most frequent ethical issue in practice was end-of-life care among responded hospitals, however, the role of HECs was not clearly separated from that of Institutional Review Board.

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません。